Long-term treatment for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This trial is for people who have already completed a previous study of the drug GST-HG141 (Nairevir) and are now continuing with the same drug plus a nucleoside analog (a standard antiviral). It aims to see how safe and effective this combination is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have completed the earlier GST-HG141 study without stopping early and took your medication as directed at least 80% of the time.
- Your liver enzyme (ALT) level is no more than 5 times the upper limit of normal.
- You are willing to continue long-term treatment with the study drug plus a nucleoside analog.
- If you or your partner can have children, you agree to use effective birth control during the study and for 28 days after stopping.
- You do not have severe infections, liver cirrhosis, liver cancer, or other serious medical conditions that would make the study unsafe.
- Your blood tests meet certain minimum levels (e.g., platelets, white blood cells, kidney function) and your total bilirubin is not too high.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.